TEL AVIV, Israel, Aug. 23, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today issued a stockholder update on its Evolving Marketing Strategy for skin cancer diagnostic solutions. The adopted strategy represents an entrepreneurial concept approach to locating and initiating opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS") to grow the company and become a leading industry player.
The initially targeted countries are the USA, Russia and the CIS, Australia, Germany, Japan, and Israel.
The Basic Strategy concept is a four pillar structure: Preliminary logistics for initiation and maintenance of service for large volume of demand for the device; Advanced survey to define all relevant aspects (Production, Distribution, Tech Support); Survey of the specific targeted regions; Locate and engage a distributor, meeting with the requirements, in the defined country/state/ region.
The marketing strategy in every country will be basically similar and will be executed in similar initial stages. The differences will be the result of health reimbursement programs, Medicare concept, and conduct of distribution and use of medical devices.
mBeach is clearly focused on meeting this growing market need for a safe, non-intrusive technology to detect skin cancer.
mBeach CEO Yossi Biderman commented, "The marketing strategy we have defined at this early stage is due to the lengthy regulatory procedures in each country. We expect that the mutual impact of market demand and technical innovative approach on the final product will result in what we think will be a most advanced, adaptable, and technically supported, medical device for the early detection of skin cancer. We expect our SkinScan 650, a non-invasive, point-of-care, doctors' decision supporting device, to provide the Medical practitioner a much needed user friendly diagnostic solution."
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. It will help reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.